HTG Molecular Diagnostics (NASDAQ:HTGM) is set to release its earnings data after the market closes on Thursday, November 8th. Analysts expect HTG Molecular Diagnostics to post earnings of ($0.19) per share for the quarter.
HTG Molecular Diagnostics (NASDAQ:HTGM) last posted its quarterly earnings data on Thursday, August 9th. The medical research company reported ($0.14) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.19) by $0.05. HTG Molecular Diagnostics had a negative return on equity of 132.67% and a negative net margin of 81.10%. The firm had revenue of $4.91 million for the quarter, compared to the consensus estimate of $5.30 million. On average, analysts expect HTG Molecular Diagnostics to post $-1 EPS for the current fiscal year and $-1 EPS for the next fiscal year.
NASDAQ:HTGM opened at $3.81 on Thursday. HTG Molecular Diagnostics has a 52-week low of $1.71 and a 52-week high of $5.83. The company has a debt-to-equity ratio of 0.35, a quick ratio of 9.29 and a current ratio of 9.50. The firm has a market cap of $106.58 million, a price-to-earnings ratio of -2.13 and a beta of 1.79.
Several research firms have issued reports on HTGM. HC Wainwright set a $7.00 price objective on HTG Molecular Diagnostics and gave the stock a “buy” rating in a report on Wednesday, October 24th. ValuEngine downgraded HTG Molecular Diagnostics from a “buy” rating to a “hold” rating in a report on Thursday, July 19th. Leerink Swann reaffirmed an “outperform” rating on shares of HTG Molecular Diagnostics in a report on Monday, July 9th. Zacks Investment Research downgraded HTG Molecular Diagnostics from a “buy” rating to a “hold” rating in a report on Wednesday, October 10th. Finally, Cantor Fitzgerald began coverage on HTG Molecular Diagnostics in a report on Thursday, September 20th. They set a “buy” rating and a $7.00 price objective on the stock. One analyst has rated the stock with a hold rating and five have given a buy rating to the company. HTG Molecular Diagnostics has a consensus rating of “Buy” and a consensus price target of $6.25.
About HTG Molecular Diagnostics
HTG Molecular Diagnostics, Inc develops and markets products and services based on proprietary technology that facilitates the routine use of targeted molecular profiling. The company offers instrumentation (or platforms); consumables comprising assay kits; and software analytics that automate sample processing and profiles various molecular targets.
Featured Story: Stop Order
Receive News & Ratings for HTG Molecular Diagnostics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for HTG Molecular Diagnostics and related companies with MarketBeat.com's FREE daily email newsletter.